Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serene Study of selexipag after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension
jRCTs051240260Active, not recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of selexipag in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Nippon Shinyaku. Primary endpoint: Change in mPAP/CO slope during CPET. Started Jun 2025; status: active, not recruiting.
02
Drugs
selexipag
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on jRCTs051240260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240260.